Regorafenib plus nivolumab in patients with mismatch repair-proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 studyResearch in context

Summary: Background: Anti-programmed cell death protein 1 antibodies plus multikinase inhibitors have shown encouraging activity in several tumour types, including colorectal cancer. This study assessed regorafenib plus nivolumab in patients with microsatellite stable/mismatch repair-proficient met...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Marwan Fakih, Kanwal Pratap Singh Raghav, David Z. Chang, Tim Larson, Allen L. Cohn, Timothy K. Huyck, David Cosgrove, Joseph A. Fiorillo, Rachel Tam, David D'Adamo, Neelesh Sharma, Barbara J. Brennan, Ying A. Wang, Sabine Coppieters, Hong Zebger-Gong, Anke Weispfenning, Henrik Seidel, Bart A. Ploeger, Udo Mueller, Carolina Soares Viana de Oliveira, Andrew Scott Paulson
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Elsevier 2023-04-01
Schriftenreihe:	EClinicalMedicine
Schlagworte:	Regorafenib Nivolumab Microsatellite stable Mismatch repair-proficient Metastatic colorectal cancer
Online-Zugang:	http://www.sciencedirect.com/science/article/pii/S2589537023000949
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!